- Home
- GASS vs XFOR Comparison
GASS vs XFOR Comparison
Compare GASS & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GASS | XFOR |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.4M | 377.3M |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GASS | XFOR |
|---|---|---|
| Price | $9.65 | $3.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 113.5K | ★ 803.3K |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.00 | ★ N/A |
| Revenue Growth | N/A | ★ 150.00 |
| 52 Week Low | $6.12 | $2.80 |
| 52 Week High | $10.55 | $4.83 |
Technical Indicators
Market Signals| Indicator | GASS | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 37.73 |
| Support Level | $9.10 | $3.19 |
| Resistance Level | $9.81 | $3.56 |
| Average True Range (ATR) | 0.27 | 0.26 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 57.76 | 29.17 |
Price Performance
Historical ComparisonAbout GASS StealthGas Inc.
StealthGas Inc is an international shipping transportation company. It owns liquefied petroleum gas (LPG) pressurized carriers and provides international seaborne transportation services to LPG producers and users, as well as crude oil and product carriers to oil producers, refineries, and commodities traders. The company carriers carry various petroleum gas products in liquefied forms, such as propane, butane, butadiene, isopropane, propylene, and vinyl chloride monomer, which are all byproducts of the production of crude oil and natural gas.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.